Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes

Author:

Looker Helen C., ,Colombo Marco,Agakov Felix,Zeller Tanja,Groop Leif,Thorand Barbara,Palmer Colin N.,Hamsten Anders,de Faire Ulf,Nogoceke Everson,Livingstone Shona J.,Salomaa Veikko,Leander Karin,Barbarini Nicola,Bellazzi Riccardo,van Zuydam Natalie,McKeigue Paul M.,Colhoun Helen M.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference37 articles.

1. U.S. Food and Drug Administration (2008) Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. U.S. Food and Drug Administration, Silver Spring

2. Innovative Medicines Initiative (2010) Summit. Available from www.imi.europa.eu/content/summit . Accessed 30 Oct 2014

3. Pearson ER, Donnelly LA, Kimber C et al (2011) Variation in TCF7l2 influences therapeutic response to sulfonylureas—a GoDARTs study. Diabetes 56:2178–2182

4. Ahluwalia TS, Lindholm E, Groop LC (2011) Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 54:2295–2302

5. Malarstig A, Silveira A, Wagsater D et al (2011) Plasma CD93 concentration is a potential novel biomarker for coronary artery disease. J Intern Med 270:229–236

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3